Several studies have been devoted to cross-linked sodium chondroitin sulphate (SCS), in the context of numerous strategies attempting to target the colon for the absorption or the therapeutic action of a drug. SCS, a glycosaminoglycan presenting a specific degradation in the colon, is in fact soluble in water and its use as drug carrier at such a distance from the digestive tube necessitates its hydrophobisation. One method described in the literature consists in manufacturing a three-dimensional network by cross-linking with bifunctional compounds. However, all the structural characterisations carried out on the products resulting from the catalysed treatments of SCS with diaminoalkanes demonstrate that there are no cross-linking bridges between the polymer chains. Moreover, treated SCS-based tablets containing theophylline as model drug lead in vitro to dissolution profiles which are identical to those obtained with the non-treated SCS. We were therefore unable to find the announced results using the method described.
1. Rao, S. S. and W. A. Ritschel. 1992. "Development and in vitro/in vivo Evaluation of a Colonic Release Capsule of Vasopressin,"Int. J. of Pharmaceutics, 86:35-41.
2.
2. Silk, D.1993. The Int. J. of Appl. and Nutr. Sciences, 9(5):399-405.
3.
3. Gazzaniga, A., P. Iamartino, G. Maffione and M. E. Sangalli. 1994. "Oral Delayed Release System for Colonic Specific Delivery,"Int. J. of Pharmaceutics, 108:77-83.
4.
4. Wilding, I. R., S. S. Davis, F. Pozzi, P. Furlani and A. Gazzaniga. 1994. "Enteric Coated Timed Release Systems for Colonic Targeting,"Int. J. of Pharmaceutics, 111:99-102.
5.
5. Kimura, T., K. Sudo, Y. Kanzaki, K. Mikil, Y. Takeichi, Y. Kurosaki and T. Nakoyama. 1994. Biol. Pharm. Bull., 17(2):327-333.
6.
6. Kraeling, M. E. K. and W. A. Ritschel. 1992. "Development of a Colonic Release Capsule Dosage Form and the Absorption of Insulin,"Pharmacol., 14(3): 199-209.
7.
7. Vandelli, M. A., E. Leo, F. Forni and M. T. Bernabei. 1996. "In vitro Evaluation of a Potential Colonic Delivery System that Releases Drug after a Controllable Lag Time,"Eur. J. Pharm. Biopharm., 43(2):148-151.
8.
8. Gazzaniga, A., C. Busetti, L. Moro, M. E. Sangalli and F. Giordano. 1995. "Time Dependent Oral Delivery Systems for Colon Targeting,"STP Pharma Sciences, 5(1):83-88.
9.
9. Truelove, S. C., G. Watkinson and G. Draper. 1962. "Comparison of Corticosteroid and Sulphasalazine Therapy in Ulcerative Colitis,"Br. Med. J., 2:1708.
10.
10. Klotz, U.1985. "Clinical Pharmacokinetics of Sulphasalazine, Its Metabolites and the Prodrugs of 5-Aminosalicylic Acid,"Clin. Pharmacokin., 10:285-302.
11.
11. Selby, W. S., G. D. Barr, A. Ireland, C. H. Mason and D. P. Jewell. 1985. "Olsalazine in Active Colitis,"Br. Med. J., 291:1373.
12.
12. Van Hogezand, R. A.1988. "Pharmacokinetic of Olsalazine and Its Metabolites,"Scand. J. Gastroenterology, (Suppl.), 23:17.
13.
13. Tozer, T. N., J. Rigod, A. D. McLeod, R. Gungon, M. K. Hoag and D. R. Friend. 1991. "Colon Specific Delivery of Dexamethasone from a Glycoside Prodrug in the Guinea Pig,"Pharm. Res., 18(4):445-454.
14.
14. Friend, D. R. and T. N. Tozer. 1992. "Drug Glycosides in Oral: Specific Drug Delivery,"J. of Control Rel., 19:109-209.
15.
15. Haeberlin, B., W. Rubas, H. W. Nolen, III and D. R. Friend. 1993. "In vitro Evaluation of Dexamethasone β-D Glucuronide for Colon Specific Drug Delivery,"Pharm. Res., 10(11):1553-1562.
16.
16. Harboe, E., M. Johansen and C. Larsen. 1988. "Macromolecular Prodrugs VI: Coupling of Naproxen to Dextrans and in vitro Characterization of the Conjugates,"Farm. Sci. Ed., 16:73-85.
17.
17. McLeod, A. D., D. R. Friend and T. N. Tozer. 1993. "Synthesis and Chemical Stability of Glucocorticoid Dextran Esters: Potential Prodrugs for Colon Specific Delivery,"Int. J. of Pharm., 92:105-114.
18.
18. Saffran, M., G. S. Kumar, C. Savariar, J. C. Burnham, E. Williams and D. C. Neckers. 1986. "A New Approach to the Oral Administration of Insulin and Other Peptide Drugs,"Science, 233:1081-1084.
19.
19. Saffran, M., G. S. Kumar, D. C. Neckers, J. Pena, R. H. Jones and J. B. Field. 1990. "Biodegradable Azopolymer Coating for Oral Delivery of Peptide Drugs,"Biochem. Soc. Trans., 18:752-754.
20.
20. Kopecek, J., P. Kopecekova, H. Brondsted, B. Rathi, P. Yeh and K. Ikesue. 1992. "Polymers for Colon Specific Drug Delivery,"J. Control. Rel., 19:121-130.
21.
21. Kimura, Y., Y. Makita, T. Kumagai, H. Yamane, T. Kitao, H. Sasatani and S. I. Kin. 1992. "Degradation of Azo Containing Polyurethane by the Action of Intestinal Flora: Its Mechanism and Application as a Drug Delivery System,"Polymer, 33:5294-5299.
22.
22. Van den Mooter, G., C. Samyn and R. Kinget. 1992. "Azopolymers for Colon Specific Drug Delivery,"Int. J. Pharm., 87:37-46.
23.
23. Van den Mooter, G., C. Samyn and R. Kinget. 1993. "Azopolymers for Colon Specific Drug Delivery II: Influence of the Type of Azopolymer on the Degradation by Intestinal Microflora,"Int. J. Pharm., 97:133-139.
24.
24. Milojevic, S., J. M. Newton, J. H. Cummings, G. R. Gibson, R. L. Botham, S. G. Ring, M. C. Allwood and M. Stockham. 1993. "In vitro and in vivo Evaluation of Amylose Coated Pellets for Colon Specific Drug Delivery,"Proceed. Intern. Symp. Control. Rel. Bioact Mater, Controlled Release Society Inc., 20:288-289.
25.
25. Milojevic, S., J. M. Newton, J. H. Cummings, G. R. Gibson, R. L. Botham, S. G. Ring, M. Stockham and M. C. Allwood. 1996. "Amylose as a Coating for Drug Delivery to the Colon: Preparation and in vitro Evaluation Using 5-Aminosalicylic Acid Pellets,"J. of Control. Rel., 38:75-84.
26.
26. Bauer, K. H. and C. Wohschlegel. 1992. "Review About Novel Pharmaceutical Excipients for Colon Targeting,"Drugs Made in Germany, 35(3):85-89.
27.
27. Hovgaard, L. and H. Brondsted. 1995. "Dextran Hydrogels for Colon Specific Delivery,"J. of Control. Rel., 36:159-166.
28.
28. Rubinstein, A., R. Radai, M. Ezra, S. Pathak and J. S. Rokem. 1993. "In vitro Evaluation of Calcium Pectinate: A Potential Colon Specific Drug Delivery Carrier,"Pharm. Res., 10:258-263.
29.
29. Ashford, M., J. Fell, D. Attwood, H. Sharma and P. Woodhead. 1994. "Studies on Pectin Formulations for Colonic Drug Delivery,"J. of Control. Rel., 30:225-232.
30.
30. Rubinstein, A. and Radai, R.1995. "In vitro and in vivo Analysis of Colon Specificity of Calcium Pectinate Formulations,"Eur. J. Pharm. Biopharm., 41(5):291-295.
31.
31. Rubinstein, A., D. Nakar and A. Sintov. 1992. "Colonic Drug Delivery: Enhanced Release of Indomethacin from Cross-Linked Chondroitin Sulfate Matrix in Rat Cecal Content,"Pharm. Res., 9:276-278.
32.
32. Rubinstein, A., D. Nakar and A. Sintov. 1992. "Chondroitin Sulfate: A Potential Biodegradable Carrier for Colon Specific Drug Delivery,"Int. J. of Pharm., 84:141-150.
33.
33. Sintov, A. and A. Rubinstein. 1991. "Colonic Drug Delivery System," Int. Patent A61K9/14, WO 91/16881.
34.
34. Volpi, N.1993. "Extraction, Purification and Physico-Chemical Properties of Glycosaminoglycans,"Boll. Chim. Farmaceutico, 132(5):153-160.
35.
35. Yamagata, T., H. Saito, O. Habuchi and S. Suzuki. 1968. "Purification and Properties of Bacterial Chondroitinases and Chondrosulfatase,"The J. of Biological Chem., 243(7):1523-1535.
36.
36. Salyers, A. A.1979. "Energy Sources of Major Intestinal Fermentative Anaerobes,"Am. J. Clin. Nutr., 32:153-158.
37.
37. Salyers, A. A. and M. O'Brien. 1980. "Cellular Location of Enzymes Involved in Chondroitin Sulfate Breakdown by Bacteroides Thetaiotaomicron,"J. of Bact., 143(2):772-780.
38.
38. Guthrie, E. P. and A. A. Salyers. 1986. "Use of Targeted Insertional Mutagenesis to Determine whether Chondroitin Lyase II is Essential for Chondroitin Sulfate Utilization by Bacteroides Thetaiotaomicron,"J. of Bacteriology, 166(3):966-971.
39.
39. Gu, K., J. Liu, A. Pervin and R. J. Linhardt. 1993. "Comparison of the Activity of Two Chondroitin AC Lyases on Dermatan Sulfate,"Carbohydrate Res., 244:369-372.
40.
40. Takegawa, K., K. Iwahara and S. Iwahara. 1993. "Effect of Mucopolysaccharides on Chondroitinases Production and Rapide Isolation of Chondroitinases,"Tech. Bull. Agr. Kagawa Univ., 45(2):111-114.
